The estimated Net Worth of Kevin Young is at least $3.55 Million dollars as of 13 May 2019. Mr. Young owns over 30,000 units of Cortexyme Inc stock worth over $58,500 and over the last 20 years he sold CRTX stock worth over $3,021,000. In addition, he makes $472,504 as Independent Director at Cortexyme Inc.
Kevin has made over 18 trades of the Cortexyme Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently he bought 30,000 units of CRTX stock worth $510,000 on 13 May 2019.
The largest trade he's ever made was exercising 460,746 units of Cortexyme Inc stock on 16 November 2012 worth over $12,214,376. On average, Kevin trades about 17,504 units every 81 days since 2004. As of 13 May 2019 he still owns at least 30,000 units of Cortexyme Inc stock.
You can see the complete history of Mr. Young stock trades at the bottom of the page.
Kevin B. Young CBE. serves as Independent Director of the Company. Mr. Young served as the Chief Operating Officer and Executive Vice President of Commercial Operations for Gilead Sciences, Inc. from 2004 to 2018. Mr. Young previously held positions at ICI Pharmaceuticals and Amgen, Inc., where Mr. Young was Head of the U.S. Inflammation Business Unit from 2001 to 2004. Mr. Young holds undergraduate and graduate degrees in Sports Science and Exercise from Liverpool John Moores University and the University of Nottingham, respectively, and has completed the Executive Program at the University of Michigan, School of Business Administration. Mr. Young was appointed a commander of the Most Excellent Order of the British Empire, recognizing his services to the healthcare and pharmaceutical industries.
As the Independent Director of Cortexyme Inc, the total compensation of Kevin Young at Cortexyme Inc is $472,504. There are 11 executives at Cortexyme Inc getting paid more, with Michael Detke having the highest compensation of $1,100,170.
Kevin Young is 62, he's been the Independent Director of Cortexyme Inc since 2019. There are 3 older and 15 younger executives at Cortexyme Inc. The oldest executive at Cortexyme Inc is Una Ryan, 78, who is the Lead Independent Director.
Kevin's mailing address filed with the SEC is C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO, CA, 94080.
Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi, and Ansbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
Cortexyme Inc executives and other stock owners filed with the SEC include: